10% Off
Romerol2 mg
Drug International Ltd.
৳4.50
Add to cart
Generic medicine
Rosiglitazone: Brands, Price & Uses in Bangladesh
Rosiglitazone is a thiazolidinedione (TZD) class oral antidiabetic agent approved for the management of type 2 diabetes mellitus in adults and more.
About Rosiglitazone
Indications of Rosiglitazone
Rosiglitazone is a thiazolidinedione (TZD) class oral antidiabetic agent approved for the management of type 2 diabetes mellitus in adults, used to improve glycemic control in conjunction with diet and exercise.
Established/FDA-approved uses
- Monotherapy: Rosiglitazone may be used as a single agent when diet and exercise alone do not adequately control blood glucose.
- Combination therapy: Rosiglitazone may be used together with metformin or a sulfonylurea when either agent alone, plus diet and exercise, does not achieve adequate glycemic control.
Important note on current use
Use of Rosiglitazone has declined substantially since post-marketing data raised concerns about cardiovascular safety (see Precautions and Warnings). It is no longer considered a first-line antidiabetic and, in many regulatory jurisdictions, its use is now restricted to patients who cannot achieve glycemic control with other agents and for whom the potential benefit is judged to outweigh cardiovascular risk after individualized discussion. Rosiglitazone is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis, and is not a substitute for insulin in patients who require insulin.
Dosage & Administration of Rosiglitazone
Adult dosing
| Regimen | Dose |
|---|---|
| Monotherapy or combination (initial) | Rosiglitazone 4 mg orally once daily, or 2 mg twice daily |
| Titration | May be increased to 8 mg/day (once daily or in two divided doses) after 8-12 weeks if fasting glucose response is inadequate |
Administration
Rosiglitazone may be taken with or without food, at approximately the same time each day. Tablets should be swallowed whole and not crushed or split unless scored for that purpose.
Special populations
See Use in Special Populations for hepatic, renal, and combination-therapy dose considerations. Rosiglitazone is not recommended in patients with active liver disease (see Contraindications).
Side Effects of Rosiglitazone
Adverse effects reported with Rosiglitazone include:
Common
- Upper respiratory tract infection, headache
- Weight gain
- Mild-to-moderate peripheral edema (fluid retention)
- Anemia (usually dilutional, from increased plasma volume)
- Increases in total and LDL cholesterol
Serious (less common but clinically important)
- New-onset or worsening congestive heart failure (see Contraindications and Precautions)
- Increased risk of myocardial ischemic events reported in post-marketing meta-analyses, contributing to restricted use of Rosiglitazone (see Precautions and Warnings)
- Increased incidence of bone fractures, particularly in women, typically involving the distal upper limb and foot
- Hepatotoxicity (rare; periodic liver function monitoring is advised)
- Macular edema (rare)
Contraindications of Rosiglitazone
Rosiglitazone is contraindicated in patients with:
- Known hypersensitivity to Rosiglitazone or any component of the formulation.
- Established New York Heart Association (NYHA) Class III or IV heart failure.
- Active liver disease (including significantly elevated liver enzymes at baseline).
Frequently Asked Questions about Rosiglitazone
What is Rosiglitazone used for?
Rosiglitazone is used to help control blood sugar levels in adults with type 2 diabetes mellitus, either alone or in combination with metformin or a sulfonylurea, alongside diet and exercise. Its use has become more restricted over time due to cardiovascular safety concerns identified after approval.
Why has the use of Rosiglitazone declined?
Post-marketing studies raised concerns that Rosiglitazone may increase the risk of heart-related ischemic events (such as heart attack) and can cause or worsen heart failure. Because of this, Rosiglitazone is no longer considered a first-line treatment and is now used mainly as a restricted, second-line option after other treatments have failed or are unsuitable, following careful discussion of risks and benefits with a physician.
Can I take Rosiglitazone if I have heart failure?
No. Rosiglitazone is contraindicated in patients with established NYHA Class III or IV heart failure because it can cause fluid retention that worsens heart failure. Even in milder heart failure, it should be used only with caution and close monitoring for weight gain, swelling, or shortness of breath.
Is Rosiglitazone safe during pregnancy or breastfeeding?
Rosiglitazone is not generally recommended during pregnancy because insulin is usually preferred for blood sugar control in pregnant women, and safety data on Rosiglitazone in pregnancy are limited; it should only be used if clearly needed and a physician judges the benefit outweighs the potential risk to the baby. Because it is not known whether Rosiglitazone passes into breast milk, a decision should be made with a physician about whether to continue breastfeeding or continue Rosiglitazone.
What are the most important side effects of Rosiglitazone to watch for?
Watch for signs of fluid retention or heart failure (swelling, rapid weight gain, shortness of breath), chest pain or symptoms of a possible heart problem, signs of liver problems (yellowing of skin/eyes, dark urine, unusual fatigue), unexplained bone pain or fractures, and any new vision changes (which could indicate macular edema). Seek medical attention promptly if any of these occur.
What should I do if I take too much Rosiglitazone?
If an overdose of Rosiglitazone is suspected, seek immediate medical attention or contact a poison control center right away. Do not try to treat an overdose at home; supportive care from a medical professional is required.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.